UPDATE 2-Gilead 4th-qtr profit misses Wall Street estimate, shares fall

Gilead Sciences Inc on Monday reported a fourth-quarter profit that fell short of Wall Street estimates, sending shares lower, as sales of its flagship hepatitis C treatments continued to slide and it recorded one-time charges, and the company .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.